Market closedNon-fractional
Esperion Therapeutics/ESPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Esperion Therapeutics
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Ticker
ESPR
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Ann Arbor, United States
Employees
-
Website
www.esperion.com
ESPR Metrics
BasicAdvanced
$460M
Market cap
-
P/E ratio
-$0.69
EPS
1.02
Beta
-
Dividend rate
Price and volume
Market cap
$460M
Beta
1.02
Financial strength
Current ratio
2.222
Quick ratio
1.709
Long term debt to equity
-170.863
Total debt to equity
-186.502
Interest coverage (TTM)
-0.59%
Management effectiveness
Return on assets (TTM)
-6.94%
Return on equity (TTM)
27.73%
Valuation
Price to revenue (TTM)
1.331
Price to book
-1.55
Price to tangible book (TTM)
-1.55
Price to free cash flow (TTM)
-11.168
Growth
Revenue change (TTM)
183.74%
Earnings per share change (TTM)
-79.63%
3-year revenue growth (CAGR)
-0.57%
3-year earnings per share growth (CAGR)
-50.78%
What the Analysts think about ESPR
Analyst Ratings
Majority rating from 8 analysts.
ESPR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$138M
327.64%
Net income
$61M
-208.35%
Profit margin
44.29%
-125.33%
ESPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.46
-$0.37
-$0.50
$0.34
-
Expected
-$0.61
-$0.43
-$0.48
$0.05
-$0.18
Surprise
-24.75%
-14.40%
3.63%
627.27%
-
ESPR News
AllArticlesVideos
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
GlobeNewsWire·2 weeks ago
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
GlobeNewsWire·4 weeks ago
Esperion to Participate in Upcoming June Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Esperion Therapeutics stock?
Esperion Therapeutics (ESPR) has a market cap of $460M as of July 27, 2024.
What is the P/E ratio for Esperion Therapeutics stock?
The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of July 27, 2024.
Does Esperion Therapeutics stock pay dividends?
No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Esperion Therapeutics dividend payment date?
Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Esperion Therapeutics?
Esperion Therapeutics (ESPR) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Esperion Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.